It’s a scary time for intellectual property stakeholders in life science industries. Even if you can get your claims past the batty patent eligibility jurisprudence you still have to fight your way through the old cobwebs of obviousness and enablement. With the constant threat of inter partes review, post grant review, and even covered¬† business … Continue reading this entry